Market Overview
The global Dyslipidaemia Drug Market was valued at USD 14.54 billion in 2024 and is projected to reach nearly USD 19.15 billion by 2032, growing at a CAGR of 3.5% during the forecast period from 2025 to 2032. Increasing cardiovascular disease prevalence, growing awareness of cholesterol management, an ageing population, and advancements in lipid-lowering medications are...
